Vical (VICL) Scheduled to Post Quarterly Earnings on Thursday

Vical (NASDAQ:VICL) is scheduled to be announcing its n/a earnings results before the market opens on Thursday, March 15th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Shares of Vical (NASDAQ VICL) opened at $1.53 on Wednesday. Vical has a 12-month low of $1.32 and a 12-month high of $3.70. The stock has a market cap of $19.29, a P/E ratio of -1.43 and a beta of 1.33.

In related news, major shareholder Armistice Capital Master Fund acquired 100,000 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was purchased at an average cost of $1.43 per share, for a total transaction of $143,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.88% of the company’s stock.

A number of equities research analysts have recently issued reports on VICL shares. Zacks Investment Research upgraded shares of Vical from a “sell” rating to a “hold” rating in a research report on Saturday, December 2nd. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Vical in a research report on Tuesday, November 21st. Finally, ValuEngine upgraded Vical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $7.00.

TRADEMARK VIOLATION NOTICE: “Vical (VICL) Scheduled to Post Quarterly Earnings on Thursday” was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at

About Vical

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Earnings History for Vical (NASDAQ:VICL)

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with's FREE daily email newsletter.

Leave a Reply